Monthly Archives: February 2019
P057 INFLIXIMAB TREATMENT INTENIFICATION BASED ON ENDOSCOPIC ACTIVITY CONTRIBUTES TO CLINICAL RESPONSE IN PATIENTS WITH CROHN’S DISEASE
Infliximab (IFX) treatment intensification, consisting of dose escalation or interval shortening, is effective for restoring clinical response in patients with Crohn’s disease (CD). However, clinical data on the timing of IFX treatment intensificatio… Continue reading
P058 LOW DOSE METHOTREXATE HAS SIMILAR OUTCOMES AS HIGH-DOSE METHOTREXATE IN COMBINATION WITH ANTI-TNF THERAPY IN INFLAMMATORY BOWEL DISEASES
Methotrexate (MTX) is a well-known immunomodulator in the treatment of inflammatory bowel disease (IBD) and often combined with biological agents. The ideal MTX dose for combination therapy has not been determined. Our aim is to investigate the effect … Continue reading
P059 RACIAL VARIATION IN MYELOSUPPRESSION HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS
Thiopurine therapy is used as a standard of care in inflammatory bowel disease (IBD), but it might cause fatal myelosuppressive adverse events that require hospitalization. To reduce the risk of myelosuppression hospitalizations, a systematic clinical … Continue reading
P060 COMBINATION THERAPY WITH TNF-INHIBITORS AND IMMUNOMODULATORS ARE ASSOCIATED WITH SHORTER DURATION TO FIRST SERIOUS INFECTION – THE DEVELOP EXPERIENCE
DEVELOP is a multicenter, international, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients (pts) with inflammatory bowel disease (IBD) diagnosed prior to 18 years of age who were treated with ant… Continue reading
P061 CYCLOSPORINE INDUCED KAPOSI SARCOMA IN AN IBD PATIENT: A DOWNWARD SPINDLE
Kaposi Sarcoma is an angioproliferative neoplasm found to be associated with human herpesvirus-8 (HHV8). Although this virus plays a role in the pathogenesis of the disease, in individuals who are human immunodeficiency virus (HIV) negative, it is exce… Continue reading
P062 DOSE ESCALATION WITH ORIGINATOR INFLIXIMAB OR COMBINATION THERAPY WITH ORIGINATOR INFLIXIMAB AND IMMUNOMODULATORS SIGNIFICANTLY INCREASES RISK FOR SERIOUS ADVERSE EVENTS IN PEDIATRIC IBD – THE DEVELOP EXPERIENCE
DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical status of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease [CD], ulcerative colitis [UC], or indeterminate colitis [IC]) t… Continue reading
P063 SAFETY OF BIOLOGIC THERAPY IN OLDER PATIENTS WITH IMMUNE-MEDIATED DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Lifelong immunosuppression is a cornerstone of management of immune-mediated inflammatory diseases (IMD). Older patients represent an increasingly large number of patients with these diseases but are particularly vulnerable to safety risks with therapy… Continue reading
P064 TREATMENT OF CROHN’S DISEASE AND ULCERATIVE COLITIS WITH PROTON PUMP INHIBITORS: EFFECT ON BONE LOSS AT DENTAL IMPLANTS
Proton pump inhibitors (PPI) are used to reduce the clinical manifestations of gastrointestinal reflux disease, but there is an increased risk of complications from Crohn’s disease and ulcerative colitis (IBD) associated with the use of PPI. PPI may … Continue reading
P065 VEDOLIZUMAB RELATED INFUSION REACTIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED IN AN ALTERNATE CARE SETTING
Several studies have indicated that home infusions of biologic agents are safe for selected patients with inflammatory bowel disease. Vedolizumab is a monoclonal antibody directed against the α4β7 integrin and is indicated for the treatment of modera… Continue reading
02 NEW ONSET AUTOIMMUNE DISORDERS, PRIMARILY PSORIASIS, IN ANTI-TNF BIOLOGIC EXPOSED PEDIATRIC PATIENTS – THE DEVELOP EXPERIENCE
DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical outcomes of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn’s disease, ulcerative colitis, or indeterminate colitis) treated with a… Continue reading